ATCC

Cultivarium and ATCC Support iGEM Teams Striving to Advance the Field of Synthetic Biology

Retrieved on: 
Tuesday, April 2, 2024
Agriculture, BioBrick, Synthetic biology, Education, College of Engineering (KNUST), Climate change, Health, Collection, International, Research, ATCC, Biotechnology, Creativity, Doctor of Philosophy

WATERTOWN, Mass. and MANASSAS, Va., April 2, 2024 /PRNewswire/ -- Cultivarium, the focused research organization creating open-source tools to expand access to uncharacterized microorganisms, and ATCC, the world's premier biological materials management and standards organization, today announced a groundbreaking collaboration to help iGEM 2024 teams access non-model microbes for biotechnology. The annual iGEM Competition involves multidisciplinary student teams from across the globe that compete for medals and awards by designing, building, and testing genetically engineered systems using standard biological parts called BioBricks. Working in and outside the lab, iGEM teams aim to create sophisticated synthetic biology projects that can positively contribute to their communities and the world.

Key Points: 
  • Working in and outside the lab, iGEM teams aim to create sophisticated synthetic biology projects that can positively contribute to their communities and the world.
  • Cultivarium and ATCC are committing to empowering the creativity of iGEM teams with diverse and innovative microbial resources to expand the horizons of synthetic biology research.
  • "By pairing Cultivarium's capabilities and ATCC's enormous and taxonomically diverse collection of microbes we can support iGEM teams to be bold, creative and drive breakthroughs in synthetic biology."
  • Together, Cultivarium and ATCC are poised to revolutionize the landscape of synthetic biology by equipping iGEM teams with the tools and resources needed to tackle global challenges and unlock the full potential of non-model microbes.

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on: 
Wednesday, March 6, 2024
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Plasmid, ATCC, Multimedia, Sale, Transfection, Cell, Antibody, HEK293, Patent, Poster, Immortalised cell line, ATCC (company), AAV, Vaccine

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points: 
  • Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
  • View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
    The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
  • “The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
  • “To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
Wednesday, January 31, 2024
Misgav, MD, BIRD Foundation, Commerce, BIRD, Planner, Associate, Partnership, Yokneam Illit, Mayo Clinic, History, TEL, Carbon, Splenic infarction, Lod, Intelligence, Sheba Medical Center, Patient, Ministry, Mondelez International, NIST, Approval, Virtual reality, Anopheles, Agriculture, Anopheles stephensi, Parity, Rehovot, ATCC, Hope, Malaria, Pharmaceutical industry

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

Cell Line Development Market Research Report 2023-2030 Featuring Key Players - Thermo Fisher Scientific, Corning, Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius, Merck, Berkeley Lights, Danaher - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Health, Pharmaceutical, CLD, Research, Immortalised cell line, GMP, Thermo Fisher Scientific, Fujifilm, Type, Coronavirus, Application, Fujifilm Diosynth Biotechnologies, ATCC (company), Novartis, Sigma-Aldrich, Human, Growth, ATCC, Fine chemical, Pharmaceutical industry, Mobile phone, Vaccine, Nusinersen

Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.

Key Points: 
  • Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.
  • The expansion and growth of the biologics sector will also be a major CLD market development determinant.
  • For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021.
  • However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

Retrieved on: 
Thursday, November 30, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, AIDS, General Health, Pharmaceutical, Health, Science, NIAID, HIV/AIDS, Biology, Vaccine, DVM, Infection, National Institutes of Health, Human services, HIV, NIH, MBA, Contract research organization, Bangladesh Technical Education Board, Health department, Public, Pharmaceutical industry, ATCC

NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met.

Key Points: 
  • NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met.
  • This contract will merge the NIH HIV Reagent Program with the BEI Resources Program under the Biological and Emerging Infections Research Resources Program (BEI-RRP) umbrella.
  • ATCC has managed the BEI Resources Program since 2003 and the NIH HIV Reagent Program since 2020.
  • At the discretion of NIAID, it will also be a resource for materials produced by other government-supported research projects and service programs.

ATCC Announces Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Award from NIAID

Retrieved on: 
Tuesday, November 28, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NIAID, Disease, Acquisition, Vaccine Research Center, VRC, NIH Intramural Research Program, Air tasking order, Bioterrorism, Vaccine, Laboratory, DVM, IDIQ, API, Infection, COVID-19, Biomedical Research, NIH, MBA, Indefinite, Comprehensive, CGMP, Doctor of Philosophy, Active ingredient, Bangladesh Technical Education Board, Public, IRP, Pharmaceutical industry, ATCC

The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).

Key Points: 
  • The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
  • NIAID’s CARRRP provides the capacity and capability for a broad range of services necessary to support and conduct comprehensive and rapid biomedical research.
  • Under the CARRRP Task Order, ATCC will manage critical biomaterials for the Vaccine Research Center (VRC), one of the three intramural divisions of NIAID’s Intramural Research Program (IRP).
  • “We look forward to working with NIAID and its Intramural Research Program as part of the CARRRP.”

ATCC Products to be Used in Microgravity Experiments on the International Space Station

Retrieved on: 
Friday, November 10, 2023
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Astronaut, Singular, Medicine, ISS, Agriculture, DNA, International Space Station, ISS National Lab, DVM, SpaceX, University, Molecular reference standards, Doctor of Philosophy, NGS, ATCC

ATCC , the world’s premier biological materials management and standards organization, today announced that ATCC catalog item MSA-2003-ISS was sent to the International Space Station ( ISS National Lab ) on November 9th aboard the SpaceX CRS-29 Cargo Dragon Resupply Craft mission.

Key Points: 
  • ATCC , the world’s premier biological materials management and standards organization, today announced that ATCC catalog item MSA-2003-ISS was sent to the International Space Station ( ISS National Lab ) on November 9th aboard the SpaceX CRS-29 Cargo Dragon Resupply Craft mission.
  • “This is the first time that our products will be used in space to study microbial cells in microgravity,” said ATCC chairman and CEO Raymond H. Cypess , DVM, PhD.
  • It is a functioning research laboratory with the tools and facilities needed to translate traditional ground-based experiments into flight-ready payloads.
  • MSA-2003-ISS will be used in the uTitan DNA extraction payload studies to demonstrate extraction efficiency in zero gravity.

ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Support Its Preclinical Services for Biopharmaceutical Product Development

Retrieved on: 
Tuesday, November 7, 2023
Research, Infectious Diseases, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, National Institute of Allergy and Infectious Diseases, IND, DVM, Indefinite, NIAID, Senior, Private sector, IDIQ, NIH, Infection, Bangladesh Technical Education Board, Investigational New Drug, Pharmaceutical industry, ATCC

ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).

Key Points: 
  • ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).
  • With this contract, ATCC, as a member in the NIAID selected service provider pool, will support NIAID’s Preclinical Services for Biopharmaceutical Product Development in two main areas: the development and validation of analytical assays for product characterization and process development and formulation.
  • “This contract builds upon the work we are already doing with NIAID and several of their divisions, as well as our management of NIAID’s BEI Resources,” said Joseph Leonelli, Ph.D., Senior Vice President and General Manager of ATCC Federal Solutions.
  • “With our expertise and resources, NIAID is better able to more quickly diagnose infectious disease-causing pathogens and toxins, and then strive to develop therapeutic products to treat them.”

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

ATCC Appoints Dr. Alfredo Molinolo to Its Board of Directors

Retrieved on: 
Thursday, November 2, 2023
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Genetics, Moores Cancer Center, Biorepository, DVM, Faculty of Medical Sciences, University of Buenos Aires, Head, Publication, Doctor of Philosophy, National Institute of Dental and Craniofacial Research, Hospital Rivadavia, HNSCC, Mouse Models of Human Cancer database, Medicine, Breast cancer, Medical research, University, University of California, San Diego, Collection, Breast, Bangladesh Technical Education Board, Neck, Management, Pathology, ATCC, MD, Biology, Cancer

“Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.

Key Points: 
  • “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
  • Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
  • Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
  • “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.